Advertisement

Stimulation of Host-Defense Mechanism with Synthetic Adjuvants and Recombinant Cytokines Against Viral Infection in Mice

  • Ichiro Azuma
  • Chiaki Ishihara
  • Joji Iida
  • Yung Choon Yoo
  • Kumiko Yoshimatsu
  • Jiro Arikawa
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 319)

Abstract

The efficacy of synthetic immunoadjuvants and recombinant cytokines for the potentiation of host-resistance against virus infection was investigated using mouse models infected with Sendai virus and herpes simplex type 1 virus (HSV). The synthetic MDP derivative, MDP-Lys(L18), and recombinant cytokines, IL-1β, IFN-γ, G-CSF and GM-CSF were shown to be effective for the stimulation of nonspecific protection against Sendai virus infection in mice. Both MDP-Lys(L18) and GM-CSF were effective for the protection against HSV infection in cyclophosphamide (CY)-treated mice. B30-MDP was suggested to be useful as an immunoadjuvant for the potentiation of antigenicity of recombinant or component vaccines.

Keywords

Intranasal Administration Hemorrhagic Fever With Renal Syndrome Sendai Virus Adjuvant Activity Muramyl Dipeptide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    I. Azuma, Immunological and biochemical properties of bacterial fractions and related compounds with special reference to BCG cell wall skeleton and N. rubra cell wall skeleton, in: “Molecular and Cellular Networks for Cancer Therapy,” Y. Yamamura and I. Azuma, eds., Excerpta Medica, Tokyo, pp. 83–104 (1989).Google Scholar
  2. 2.
    F. Ellouz, A. Adam, R. Ciorubaru, and E. Lederer, Minimal structural requirements for adjuvant activity of bacterial peptidoglycan subunits, Biochem. Biophys. Res. Commun. 59: 1317 (1974).PubMedCrossRefGoogle Scholar
  3. 3.
    S. Kotani, Y. Watanabe, F. Kinoshita, T. Shimono, I. Morisaki, T. Shiba, S. Kusumoto, Y. Tarumi, and K. Ikenaka, Immunoadjuvant activities of synthetic N-acetylmuramyl-peptides or amino acids, Biken J. 18: 105 (1975).PubMedGoogle Scholar
  4. 4.
    I. Azuma, K. Nishimura, and S. Tokura, The immunological properties of chitin derivatives. — A Review, in: “Degradation and Biocompatibility of Synthetic Degradable Polymers”, D.F. Williams, ed., CRC Press, London, in press.Google Scholar
  5. 5.
    J. Iida, N. Nishi, I. Saiki, N. Mizukoshi, C. Ishihara, S. Tokura, and I. Azuma, Macrophage activation and host augmentation against Sendai virus infection with synthetic polypeptides in mice, Int. J. Immunopharm. 11: 249 (1989).CrossRefGoogle Scholar
  6. 6.
    S. Kusumoto, S. Okada, K. Yamamoto, and T. Shiba, Synthesis of 6-O-acyl derivatives of immunoadjuvant active N-acetylmuramyl-L-alanyl-D-isoglutamine, Bull. Chem. Soc. Jpn. 51: 2122 (1978).CrossRefGoogle Scholar
  7. 7.
    R. Moroi, K. Yamazaki, T. Hirota, S. Watanabe, K. Kataoka, and M. Ichinose, Physicochemical properties of muroctasin, Arzneim.-Forsch./Drug Res. 38(II): 953 (1988).Google Scholar
  8. 8.
    S. Kusumoto, M. Inage, T. Shiba, I. Azuma, and Y. Yamamura, Synthesis of long chain fatty acid esters of N-acetyl-L-alanyl-D-isoglutamine in relation to antitumor activity, Tetrahed. Lett. 49: 4899 (1978).CrossRefGoogle Scholar
  9. 9.
    C. Ishihara, N. Hamada, K. Yamamoto, J. Iida, I. Azuma, and Y. Yamamura, Effect of muramyl dipeptide and its stearoyl derivatives on resistance to Sendai virus infection in mice, Vaccine 3: 370 (1985).PubMedCrossRefGoogle Scholar
  10. 10.
    C. Ishihara, J. Iida, N. Mizukoshi, N. Yamamoto, K. Yamamoto, K. Kato, and I. Azuma, Effect of N α-acetylmuramyl-L-alanyl-D-isoglutaminyl--stearoyl-L-ly-sine on resistance to herpes simplex virus type-1 infection in cyclophosphamide-treated mice, Vaccine 7: 309 (1989).PubMedCrossRefGoogle Scholar
  11. 11.
    C. Ishihara, N. Mizukoshi, J. Iida, K. Kato, K. Yamamoto, and I. Azuma, Suppression of Sendai virus growth by treatment with N α-acetylmuramyl-L-ala-nyl-D-isoglutaminyl-N α-stearoyl-L-lysine in mice, Vaccine 5: 295 (1987).PubMedCrossRefGoogle Scholar
  12. 12.
    J. Iida, I. Saiki, C. Ishihara, and I. Azuma, Protective activity of recombinant cytokines against Sendai virus and herpes simplex virus (HSV) infections in mice, Vaccine 7: 229 (1989).PubMedCrossRefGoogle Scholar
  13. 13.
    F. Numata, K. Nishimura, H. Ishida, S. Ukei, Y. Tone, C. Ishihara, I. Saiki, I. Sekikawa, and I. Azuma, Lethal and adjuvant activities of cord factor (trehalose-6, 6′-dimycolate) and synthetic analogs in mice, Chem. Pharm. Bull. 33: 4544 (1985).PubMedCrossRefGoogle Scholar
  14. 14.
    K. Nishimura, S. Nishimura, N. Nishi, I. Saiki, S. Tokura, and I. Azuma, Immunological activity of chitin and its derivatives, Vaccine 2: 93 (1984).PubMedCrossRefGoogle Scholar
  15. 15.
    World Health Organization, Hemorrhagic fever with renal syndrome: memorandum from a WHO meeting, Bull. World Health Organ. 61: 269 (1983).Google Scholar
  16. 16.
    C. S. Schmaljohn and J.M. Dalrymple, Analysis of Hantaan virus RNA: evidence for a new genus of Bunyaviridae, Virology 131: 482 (1983).PubMedCrossRefGoogle Scholar
  17. 17.
    J. W. LeDuc, Epidemiology of hemorrhagic fever virus, J. Infect. Dis. 11 Suppl. 4: s730 (1989).CrossRefGoogle Scholar
  18. 18.
    K. Yamanishi, O. Tanishita, M. Tamura, H. Asada, K. Kondo, M. Takagi, I. Yoshida, T. Konobe, and K. Fukai, Development of inactivated vaccine against virus causing haemorrhagic fever with renal syndrome, Vaccine 6: 278 (1988).PubMedCrossRefGoogle Scholar
  19. 19.
    C. S. Schmaljohn, J. Arikawa, J.M. Dalrymple, and A.L. Schmaljohn, Expression of the envelope glycoproteins of Hantaan virus with vaccinia and baculovirus recombinants, in: “Genetics and Pathogenicity of Negative Strand Viruses”, D. Kolakofsky and B. Mahy, eds., Elsevier Biomedical Press, Amsterdam (1989).Google Scholar
  20. 20.
    C. S. Schmaljohn, Y.-K.C. Chu, A.L. Schmaljoh, and J.M. Dalrymple, Antigenic subunits of Hantaan virus expressed by baculovirus and vaccinia virus recombinants, J. Virol. 64: 3162 (1990).PubMedGoogle Scholar
  21. 21.
    I. Azuma, Development of immunostimulants in Japan, in: “Immunostimulants: Now and Tomorrow”, I. Azuma and G. Joliès, eds., Jpn. Sci. Soc. Press, Tokyo/Springer-Verlag, Berlin, pp.41–56, (1987).Google Scholar
  22. 22.
    H. Werner, Immunostimulants: The western scene, in: “Immunostimulants: Now and Tomorrow”, I. Azuma and G. Joliès, eds., Jpn. Sci. Soc. Press. Tokyo/-Springer-Verlag, Berlin, p.3 (1987).Google Scholar
  23. 23.
    A. Adam and E. Lederer, Muramyl peptides, immunomodulator, sleep factors, and vitamins, Med. Res. Rev. 4: 111 (1984).PubMedCrossRefGoogle Scholar
  24. 24.
    L. Chedid, M. Parant, P. Lefrancier, J. Choay, and E. Lederer, Enhancement of nonspecific immunity to Klebsiella pneumoniae infection by a synthetic immunoadjuvant (N-acetylmuramyl-L-alanyl-D-isoglutamine) and several analogs, Proc. Natl. Acad. Sci. USA 74: 2089 (1977).PubMedCrossRefGoogle Scholar
  25. 25.
    K. Matsumoto, H. Ogawa, T. Kusama, O. Nagase, N. Sawaki, M. Inage, S. Kusumoto, T. Shiba, and I. Azuma, Stimulation of nonspecific resistance to infection induced by 6-O-acyl muramyl dipeptide analogs in mice, Infect. Immun. 32: 748 (1981).PubMedGoogle Scholar
  26. 26.
    K. Matsumoto, H. Ogawa, O. Nagase, T. kusama, and I. Azuma, Stimulation of nonspecific resistance to infection induced by muramyl dipeptides, Microbiol. Immunol. 25: 1047 (1981).PubMedGoogle Scholar
  27. 27.
    K. Matsumoto, T. Otani, T. Une, Y. Osada, H. Ogawa, and I. Azuma, Stimulation of nonspecific resistance to infection induced by muramyl dipeptide analogs substituted in the γ-carboxy group and evaluation of N α-muramyl dipeptide-N α-stearoyllysine, Infect. Immun. 39: 1029 (1983).PubMedGoogle Scholar
  28. 28.
    K. Matsumoto, Y. Osada, T. Une, T. Otani, H. Ogawa, and I. Azuma, Anti-infectious activity of the synthetic muramyl dipeptide analogue MDP-Lys (L18), in: Immunostimulants: Now and Tomorrow,” I. Azuma and G. Joliès, eds., Jpn. Sci. Soc. Press. Tokyo/Springer-Verlag, Berlin, p.79–97 (1987).Google Scholar
  29. 29.
    T. Otani, T. Une, and Y. Osada, Stimulation of nonspecific resistance to infection by muroctasin, Arzneim.-Forsch./Drug Res. 38(II): 969 (1988).Google Scholar
  30. 30.
    I. Saiki, S. Saito, C. Fujita, H. Ishida, J. Iida, J. Murata, A. Hasegawa, and I. Azuma, Induction of tumoricidal macrophages and production of cytokines by synthetic muramyl dipeptide analogs, Vaccine 6: 238 (1988).PubMedCrossRefGoogle Scholar
  31. 31.
    F. Yamaguchi, M. Akasaki, and W. Tsukada, Induction of colony-stimulating factor and stimulation of stem cell proliferation by injection of muroctasin, Arzneim.-Forsch./Drug Res. 38(II): 980 (1988).Google Scholar
  32. 32.
    E. Tsubura, T. Nomura, H. Niitani, S. Osamura, T. Okawa, M. Tanaka, K. Ota, H. Nishikawa, T. Masaoka, M. Fukuoka, A. Horiuchi, K. Furuse, M. Ito, K. Nagai, T. Ogura, M. Kozuru, N. Hara, K. Hara, M. Ichimaru, and K. Takatsuki, Restorative activity of muroctasin on leukopenia associated with anticancer treatment, Arzneim.-Forsch./Drug Res. 38(II): 1070 (1988).Google Scholar
  33. 33.
    S. Sakamoto, T. Okawa, and N. Ogawa, Therapeutic effect of muroctasin on cancer patients with leukopenia during radiation therapy, Shin-yaku to Rinsho 38: 1407 (1989) (in Japanese).Google Scholar
  34. 34.
    T. Kataoka and T. Tokunaga, A synthetic adjuvant effective in inducing antitumor immunity, Jpn. J. Cancer Res. (Gann) 79: 817 (1988).CrossRefGoogle Scholar
  35. 35.
    T. Kataoka, M. Kinomoto, M. Takegawa, and T. Tokunaga, Effect of a synthetic adjuvant for inducing anti-tumor immunity, Vaccine in press.Google Scholar
  36. 36.
    K. Nerome, Y. Yoshioka, M. Ishida, K. Ikuma, T. Oka, T. Kataoka, A. Inoue, and A. Oya, Development of a new type of influenza subunit vaccine made by muramyldipeptide-liposome: enhancement of humoral and cellular immune responses, Vaccine 8: 503 (1990).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1992

Authors and Affiliations

  • Ichiro Azuma
    • 1
  • Chiaki Ishihara
    • 1
    • 2
  • Joji Iida
    • 1
  • Yung Choon Yoo
    • 1
  • Kumiko Yoshimatsu
    • 1
  • Jiro Arikawa
    • 1
  1. 1.Institute of Immunological ScienceHokkaido UniversitySapporoJapan
  2. 2.School of Veterinary MedicineRakuno-Gakuen UniversityEbetsuJapan

Personalised recommendations